Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.

Vogelzang, N.J., Coleman, R.E. orcid.org/0000-0002-4275-1043, Michalski, J.M. et al. (8 more authors) (2016) Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clinical Genitourinary Cancer. ISSN 1558-7673

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.clgc.2016.07.027
Keywords: Alpha-emitting radiopharmaceutical; Anemia; Castration-resistant prostate cancer; Myelotoxicity; Thrombocytopenia
Dates:
  • Published: 8 August 2016
  • Accepted: 30 July 2016
  • Published (online): 8 August 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 26 Sep 2016 15:02
Last Modified: 26 Sep 2016 15:02
Published Version: http://dx.doi.org/10.1016/j.clgc.2016.07.027
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.clgc.2016.07.027
Related URLs:

Download

Share / Export

Statistics